Investment
Features
FeesSafety
Academy
More
Pluang+

Compare DexCom, Inc. (DXCM) vs S&P Global Inc (SPGI) Price & Performance

DexCom, Inc.Trade
S&P Global IncTrade

Price performance (Past 24H)

Key statistics

DexCom, Inc. vs S&P Global Inc — how do they compare? DexCom, Inc. trades at $84.06 (market cap $31.86B), while S&P Global Inc trades at $406.3 (market cap $118.72B). The key difference: S&P Global Inc is far larger — about 3.7× DexCom, Inc.'s market cap, and S&P Global Inc pays a 0.96% dividend while DexCom, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold DexCom, Inc. for 62 Days and S&P Global Inc for 123 Days on average.

DXCMSPGI
Market Cap
$31.86B$118.72B
Volume
3,607,0701,647,917
Sector
HealthFinancials
52-Week High
$92.34$517.92
52-Week Low
$54.84$370.42
Typical Hold Time
62 Days123 Days
Enterprise Value
$31.32B$130.21B
Dividend Yield
—0.96%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

DexCom, Inc.

DXCM trades at $84.3, up 1.09% today, with a bearish technical signal despite strong fundamentals. The company reported Q2 2026 EPS of $0.70, beating estimates, continuing a trend of earnings outperformance. Revenue growth is robust, with 2025 revenue reaching $4.66 billion and net income margin improving to 20.12%. Analyst consensus is strongly bullish with an 80.77% buy rating and a $95.07 price target, suggesting significant upside from current levels.

The outlook for DXCM is positive driven by expansion in continuous glucose monitoring for Type 2 diabetes, as highlighted in recent company reports. Key risks include competitive pressures and reimbursement challenges. With solid cash flow generation and institutional support, the stock presents a growth opportunity, though investors should monitor execution against high expectations.

S&P Global Inc

S&P Global (SPGI) trades at $395.18, down 0.24% on the day, with a bearish technical signal despite strong fundamentals. The company reported robust financials with $15.34B revenue and 30.54% net income margin for 2025, while recent earnings show mixed quarterly performance. Analyst consensus remains strongly bullish with an $509.50 price target, supported by 24 buy ratings. Recent developments include expansion into digital asset risk assessment and AI-driven growth initiatives.

The stock presents a compelling long-term investment opportunity given its strong profitability, market leadership, and analyst support, though technical indicators suggest near-term caution. Key risks include market volatility and execution of growth initiatives, while the 29% upside to consensus target offers significant potential reward for patient investors.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

DXCM
100% Buy0% Sell
Avg holding period · 62 Days
SPGI
50% Buy50% Sell
Avg holding period · 123 Days

Top news

Latest headlines on both assets

About DexCom, Inc.

Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.

Read more on DXCM →

About S&P Global Inc

S&P Global provides data and benchmarks to capital and commodity market participants. In 2021 and excluding IHS Markit, S&P Ratings was over 45% of the firm's revenue and over 55% of the firm's operating income. S&P Ratings is the largest credit rating agency in the world. The firm's other segments include Market Intelligence, Indices, and Platts. Market Intelligence provides desktop tools and other data solutions to investment banks, corporations, and other entities. Indices provides benchmarks for financial markets and is monetized through subscriptions, asset-based fees, and transaction-based royalties. Platts provides benchmarks to commodity markets, principally petroleum.

Read more on SPGI →